Search

everythinglearnresearchcommunity

for

Search:↓

Dutasteride studies for hair loss are often sponsored by GlaxoSmithKline, raising concerns about potential bias. Despite this, some users report positive results with dutasteride and oral minoxidil, while others remain skeptical of industry-funded research.

Finasteride's long-term risks are often exaggerated; studies showing negative effects typically involve high doses or animal subjects. For those taking 1mg daily for hair loss, there is no significant evidence of severe side effects.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

Taking finasteride 3 times a week can provide similar benefits to daily use with potentially fewer side effects. Some users switch to topical treatments or adjust dosages to manage side effects while maintaining hair health.

A 22-year-old male has been using finasteride for a year and recently started oral minoxidil to address diffuse thinning and receding hair. He is considering switching to dutasteride for better results and reports healthier, thicker hair despite concerns about hairline and crown stability.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

A 24-year-old shared their 6-month hair regrowth progress using 1mg oral finasteride, 1ml 5% minoxidil, and 1% topical finasteride daily, noting initial side effects that subsided. They addressed vitamin D, B12 deficiencies, and thyroid issues, expressing satisfaction with the results and encouraging patience with the treatment.

The conversation discusses hair loss treatments, with the main focus on using Fluridil and considering switching to Pyrilutamide. Other treatments mentioned include minoxidil, topical finasteride, nizoral shampoo, and saw palmetto supplements, with advice to stick with Fluridil for at least six months before considering alternatives.

The user started finasteride in April 2024 after experiencing hair thinning and had been using minoxidil since January 2023. They report significant hair recovery with no side effects from finasteride, and they continue to use both treatments together.

Creatine may cause increased hair shedding in some individuals, especially those with androgenetic alopecia (AGA), despite its physical performance benefits. Many users report stopping creatine to reduce hair loss, while others believe the effects are anecdotal or due to other factors like increased physical activity.

Switching from finasteride to dutasteride for hair loss yields mixed results, with some users experiencing improvements and others facing worsening conditions or side effects like shedding. Patience is advised as dutasteride may take longer to show results, and combining treatments is suggested by some users.

The user switched from finasteride to dutasteride and noticed less hair shedding, questioning if it's due to dutasteride's effects. Others shared mixed experiences with shedding and side effects after switching, with some seeing improvements and others experiencing continued shedding.

Hair loss treatments like finasteride, minoxidil, and dutasteride are discussed, with users sharing mixed experiences about effectiveness and side effects. Some users report positive results, while others express concerns about side effects, highlighting the importance of personal choice.

The conversation discusses the effectiveness and skepticism around topical dutasteride for hair loss, with mentions of combining it with other treatments like minoxidil and oral medications. Some users doubt its efficacy due to lack of independent studies and potential conflicts of interest.

The conversation discusses the effectiveness of various doses of Dutasteride in reducing scalp DHT and its impact on hair count. Users shared personal experiences with hair loss treatments, including Dutasteride, Finasteride, and Minoxidil, with one reporting significant hair loss reduction using a combination of oral Dutasteride and topical Minoxidil and Finasteride.

User tried Dutasteride 0.5 mg twice a week and topical minoxidil for 3 months for hair loss. They are happy with the results.

Hair loss itch stopped by adding RU58841 to treatment. Topical Finasteride and Pyrilutamide also mentioned as potential itch solutions.

This conversation is about a 21-year old male's success with using finasteride, minoxidil and ketoconazole shampoo to regrow his hair. He increased the finasteride dosage from 1mg 3x per week to 1 mg daily for maximum results. People in the thread commended him on his progress.

A user's progress after three months of taking dutasteride 0.5 mg to treat their hair loss; other users suggested cutting the frizzy hair and adding minoxidil, while others cautioned against it.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.

KX-826 shows promising results for hair growth with fewer side effects, offering an alternative to finasteride and minoxidil. Users discuss combining it with minoxidil, dermarolling, and Nizoral for improved results.

Dutasteride is more effective than finasteride for hair loss, especially at the crown and midscalp, but both have similar side-effect profiles with low incidence of sexual adverse events. Improvement is measured visually, and significant results may take over 12 months to appear.

Finasteride is humorously claimed to enable communication with sea mammals, with users sharing exaggerated side effects and alternative hair loss treatments like olive oil and onion. The conversation is satirical, with users joking about unusual experiences and results.

Breezula offers modest hair growth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.

PP405 is discussed as a potential hair loss treatment, but its effectiveness and safety are uncertain. Some users express skepticism, while others are hopeful, comparing it to existing treatments like Minoxidil and Finasteride.

The conversation discusses hair loss treatments, focusing on a "natural stack" including minoxidil, microneedling, a laser helmet, saw palmetto, ketoconazole shampoo, and supplements. Many users suggest adding finasteride or dutasteride for better results, as natural methods alone may not effectively block DHT.

Stopping finasteride often leads to rapid hair loss, returning to a genetic baseline, as the drug temporarily halts hair loss and promotes regrowth. The discussion explores the complexity of hair loss, suggesting that factors beyond DHT, such as genetics and scalp conditions, may play a role.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.